Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Eli Lilly, long seen as a dominant force in obesity treatment, is facing a valuation pullback even as its underlying growth trajectory remains unusually strong for a mega-cap company.
THE APEX TIMES
THE APEX TIMES
Moderna is indicating a commercially ambitious future for its personalized cancer vaccine, even as investors and analysts continue to demand complete clinical results before fully underwriting the next phase of growth.
THE APEX TIMES
A broad decline in artificial-intelligence linked stocks on Monday left investors scanning a narrow set of catalysts, with attention centered on upcoming Nvidia results and comments tied to the Federal Reserve’s Jackson Hole meeting. Moderna, along with a mix of semiconductor, auto, and technology bellwethers highlighted in a widely read market recap, appeared on the list of stocks used to explain how the day’s trading unfolded.
THE APEX TIMES
A market-news report says Eli Lilly (LLY) has reached a $1 trillion market capitalization milestone and is positioning a path toward far higher revenue, framing the next phase around several pipeline catalysts. The post does not provide enough detail to verify timing, targets, or which programs are driving the projection.
THE APEX TIMES
A reported phase III win tied to Moderna’s cancer therapy is renewing attention on the company’s messenger RNA (mRNA) approach, even as questions about durability of clinical progress and competitive dynamics remain.
THE APEX TIMES
The biotech stock’s steep climb has been met with a sharp, single-session decline, reigniting debate over whether the move is a temporary reset or the start of a broader unwind.
THE APEX TIMES
After years of investor frustration following the post-pandemic era, Pfizer’s stock has moved back toward the top end of its 52-week range. A recent market note from Yahoo Finance said analysts are starting to revisit valuation and expectations, with particular attention to the company’s drug pipeline and its dividend.
THE APEX TIMES
A new analysis suggests Eli Lilly’s share of each sales dollar captured as operating profit has risen to levels about twice its own longer-run benchmark, and that the momentum is being supported more by sales volume than by further price gains. The durability of that mix is now the market question.
THE APEX TIMES
CVS Health said it is rebuilding a local playing field using a “Mini-Pitch System” in support of the Alex Morgan Foundation, as part of a broader, multi-year effort to revitalize sports facilities.
